Alternative Data for Reviva Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 70 | Sign up | Sign up | Sign up |
| Webpage traffic | 20,000 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 53 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 4,865 | Sign up | Sign up | Sign up |
| X Followers | 514 | Sign up | Sign up | Sign up |
| X Mentions | 25 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 20 | Sign up | Sign up | Sign up |
About Reviva Pharmaceuticals
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases.
| Price | $2.47 |
| Target Price | Sign up |
| Volume | 480,172 |
| Market Cap | $14M |
| Year Range | $2.47 - $16.8 |
| Dividend Yield | 0% |
| Analyst Rating | 50% buy |
| Industry | Biotechnology |
In the news
 |
Reviva Pharmaceuticals Holdings (RVPH) Records 37% Gain So far in 2026January 11 - Yahoo Entertainment |
 |
Bipolar Depression Market Expected to Witness Accelerated Expansion During the Forecast Period (2026-2036) Amid Advancements in Psychiatric Therapies | DelveInsightMarch 11 - PR Newswire UK |
Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption TimesMarch 8 - Benzinga |
|
Shares of pharmaceutical companies are trading lower amid overall market weakness due to the ongoing conflict in the Middle East.March 4 - Benzinga |
|
 |
12 Health Care Stocks Moving In Wednesday's Pre-Market SessionMarch 3 - Benzinga |
 |
12 Health Care Stocks Moving In Tuesday's After-Market SessionMarch 3 - Benzinga |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 0 | 0 | 0 | -4M | 0 | -0.060 |
| Q2 '25 | 0 | 0 | 0 | -6.1M | -6M | -0.120 |
| Q1 '25 | 0 | 0 | 0 | -6.4M | -6.4M | -0.150 |
| Q4 '24 | 0 | 0 | 0 | -6.3M | 0 | -0.900 |
| Q3 '24 | 0 | 0 | 0 | -8.4M | 0 | -0.250 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
Read more about Reviva Pharmaceuticals (RVPH) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews & linkedin employees.
FAQ - Reviva Pharmaceuticals
The Market Cap of Reviva Pharmaceuticals is $14M.
Currently, the price of one share of Reviva Pharmaceuticals stock is $2.47.
The RVPH stock price chart above provides a comprehensive visual representation of Reviva Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Reviva Pharmaceuticals shares. Our platform offers an up-to-date RVPH stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Reviva Pharmaceuticals (RVPH) does not offer dividends to its shareholders. Investors interested in Reviva Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Reviva Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
